Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-19-268215
Filing Date
2019-10-16
Accepted
2019-10-16 11:55:14
Documents
10
Period of Report
2019-12-05
Effectiveness Date
2019-10-16

Document Format Files

Seq Description Document Type Size
1 DEF 14A d805243ddef14a.htm DEF 14A 774643
2 GRAPHIC g805243dsp-088.jpg GRAPHIC 181874
3 GRAPHIC g805243dsp-089.jpg GRAPHIC 269728
4 GRAPHIC g805243dsp03.jpg GRAPHIC 1727
5 GRAPHIC g805243dsp26.jpg GRAPHIC 21121
6 GRAPHIC g805243dsp27.jpg GRAPHIC 27237
7 GRAPHIC g805243dsp28.jpg GRAPHIC 30549
8 GRAPHIC g805243dsp28a.jpg GRAPHIC 22308
9 GRAPHIC g805243dsp31.jpg GRAPHIC 25989
10 GRAPHIC g805243dsp32.jpg GRAPHIC 19868
  Complete submission text file 0001193125-19-268215.txt   1603698
Mailing Address 320 WAKARA WAY SALT LAKE CITY UT 84108
Business Address 320 WAKARA WAY SALT LAKE CITY UT 84108 801-584-3600
MYRIAD GENETICS INC (Filer) CIK: 0000899923 (see all company filings)

EIN.: 870494517 | State of Incorp.: DE | Fiscal Year End: 0630
Type: DEF 14A | Act: 34 | File No.: 000-26642 | Film No.: 191152282
SIC: 2835 In Vitro & In Vivo Diagnostic Substances